Top Markets
Coin of the day
Odyssey Therapeutics, Inc. Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX
Rang in aandelen #8753
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused... Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Aandeelprijs
$24.55
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$1.18B
Verandering (1 dag)
-5.50%
Verandering (1 jaar)
-
Land
US
Handel Odyssey Therapeutics, Inc. (ODTX)

Categorie

P/S-ratio voor Odyssey Therapeutics, Inc. (ODTX)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Odyssey Therapeutics, Inc. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Odyssey Therapeutics, Inc. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH